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ABSTRACT
Hyaluronic acid (HA) is abundant in tumor microenvironment and closely associated 
with invasiveness of glioblastoma (GBM) cells. However, the cellular mechanism 
underlying HA-rich microenvironment in GBM remains unexplored. Here, we show 
that tumor-associated mesenchymal stem-like cells (tMSLCs) contribute to abundance 
of hyaluronic acid (HA) in tumor microenvironment through HA synthase-2 (HAS2) 
induction, and thereby enhances invasiveness of GBM cells. In an autocrine manner, 
C5a secreted by tMSLCs activated ERK MAPK for HAS2 induction in tMSLCs. Importantly, 
HA acted as a signaling ligand of its cognate receptor RHAMM for intracellular signaling 
activation underlying invasiveness of GBM cells. Taken together, our study suggests 
that tMSLCs contribute to HA-rich proinvasive ECM microenvironment in GBM.
INTRODUCTION
Glioblastoma (GBM) is the most common and lethal 
primary brain tumor in adults [1]. Despite modern surgical 
and medical treatments, GBM still remains an incurable 
brain disease. A major barrier to the effective treatment 
of GBM is the invasiveness of these cells into brain 
parenchyma. In a process of invasion, GBM cells interact 
with a variety of extracellular matrix (ECM) molecules. 
In recent years, much attention has been devoted to ECM 
that are associated with cancer progression [2–4]. Among 
ECM components, hyaluronic acid (HA) is abundant 
in brain than other tissues, and has shown to provide 
microenvironmental cues for infiltration of GBM cells 
[5]. In addition, HA is more rich in brain tumors than 
surrounding normal brain parenchyma and its abundance 
is strongly correlated with poor prognosis of GBM patients 
[6]. HA is a large, negatively charged, unbranched polymer 
composed of repeating disaccharides of glucuronic acid 
and N-acetylglucosamine. In normal brain, HA is the 
primary ECM components and is known to exert beneficial 
effects on tissue homeostasis, the biomechanical integrity 
and structure, due to its viscosity and ability to retain 
water [5]. In pathological conditions including tumors, 
HA was found to be more enriched in the injury sites than 
normal counterpart tissues [5]. HA abundance in brain 
tumors has been known to promote motility of GBM cells 
by providing mechanical stiffening and acting as a ligand 
for intracellular signal transduction through its cognate 
receptors such as such as cluster determinant 44 (CD44), 
receptor for hyalunonate-mediated motility (RHAMM), 
and intercellular adhesion molecule-1 (ICAM-1) [5, 7, 8]. 
In accordance, the abundance of HA been proportional 
to invasiveness of tumor cells [9]. Moreover, high levels 
of HA in stroma are associated with poor prognosis of 
the patients [10]. However, although its mechanistic and 
cellular signaling functions in linkage with invasiveness 
of glioma cells are relatively well studied, the cellular 
mechanisms underlying the abundance of HA in brain 
tumors remain largely unexplored.
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Recently, tumor-associated mesenchymal stem-like 
cells (tMSLCs) are reported as stromal cells interacting 
with GBM cells and their potential role in tumor 
progression has received intensive attention [11, 12]. 
However, their role in brain tumor progression remains 
largely unknown. Moreover, their ultimate contribution 
to tumor progression still remains controversial whether 
tMSLCs play a role in cancer promotion or suppression 
[13–16]. Since those contrasting results could be caused 
by differences in their origin and/or type of tumor 
studied, we previously isolated tMSLCs from human 
GBM surgical specimens and found that their presence 
is closely correlated with the prognosis of patients 
[12]. Given that endogenous mesenchymal stem cells 
(MSCs) have a wound tropism to injury sites under 
pathological conditions such as inflammation and alters 
microenvironmental cues including ECM to repair 
damaged tissues [17], we speculated that the abundance of 
HA in GBM stroma is attributable to the ECM remodeling 
ability of tMSLCs.
In this study, we demonstrate that HA is highly 
produced in tMSLCs by autocrine loop, in which C5a 
stimulated extracellular ERK MAPK through C5a 
receptor-1 (C5aR1) for HA synthase (HAS)-2 induction. 
C5a is an N-terminal 74 amino acid fragment of the 
a-chain of the complement fifth component (C5), and is 
well known as a complement component that triggers 
degranulation of mast cells or neutrophils, enhancing 
their phagocytosis of pathogens [18]. In this study, our 
findings suggest that C5a acts as a microenvironmental 
cue activating ERK MAPK that promotes HA production 
in tMSLCs. Collectively, we demonstrate that tMSLCs 
interacting with tumor cells provide HA-rich proinvasive 
microenvironment in brain tumor.
RESULTS
tMSLCs enhances invasiveness of GBM cells by 
remodeling ECM microenvironment
To examine the effect of tMSLCs on invasiveness of 
GBM cells, we cocultured patient-derived X01 GBM cells 
with tMSLC0903 in Transwells. In this coculture, GBM cells 
were spaced from tMSLCs but crosstalk with each other 
through a porous membrane (Figure 1A). After coculture, 
invasiveness of GBM cells were analyzed in Transwells 
Figure 1: tMSLCs enhances invasiveness of GBM cells by remodeling ECM. A, B. Schematic illustration (A) and quantification 
(B) of GBM cell migration after coculture with tMSLCs in transwells. C. Schematic illustrating the experimental scheme for analysis 
of GBM cell invasiveness in collagen-based ECM preconditioned by tMSLCs. D. H&E staining and quantification of X01 GBM cells 
infiltrated into the collagen-based matrix preconditioned by tMSLCs. Scale bar, 200 μm. Data are presented as mean ± SD from one of three 
independent experiments performed. *, p < 0.05 vs. control; ***, p < 0.001 vs. control.
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pre-coated with matrigel. By coculture with tMSLCs, X01 
GBM cells adopted more invasiveness than non-cocultured 
cells (Figure 1B). In parallel, we also analyzed invasiveness 
of GBM cells in ECM conditioned by tMSLCs. To this 
end, we plated tMSLCs onto Millicell inserts containing a 
mixture of collagen type I and matrigel in growth medium, 
and allowed cells to remodel ECM for 3 d. All tMSLCs 
were then killed by treatment with puromycin, leaving ECM 
conditioned by tMSLCs, as depicted in Figure 1C. X01 GBM 
cells were then plated in this GBM cell-generated ECM, and 
their invasiveness was visualized by hematoxylin and eosin 
(H&E) staining after perpendicular sectioning of the gel 
matrix. X01 GBM cells in ECM conditioned by tMSLCs 
displayed greater infiltration than GBM cells plated on control 
ECM (Figure 1D). Taken together, these results suggest that 
tMSLCs promote invasiveness of GBM cells by providing 
extracellular components in tumor microenvironment.
tMSLCs increases HA through HAS2 induction 
in GBM microenvironment
Given that tMSLCs change ECM composition for 
invasiveness of GBM cells, we next attempted to define 
the ECM components that are increased by tMSLCs and 
are responsible for invasiveness of GBM cells. By semi-
quantitative RT-PCR, we analyzed the levels of ECM 
components that are mostly involved in GBM progression 
[19]. When those ECM components were compared 
between X01 GBM cells and tMSLCs, we found that 
HAS2 and Versican (VCAN) levels are particularly 
higher in tMSLCs than in GBM cells (Figure 2A). 
Accordingly, we depleted VCAN or HAS2 in tMSLCs 
and examined their coculture effect on migration of GBM 
cells. In wound healing assay, X01 GBM cells cocultured 
with tMSLCs more rapidly moved to fill the wound 
Figure 2: tMSLCs highly produce HA through HAS2. A. Semi-quantitative RT-PCR for ECM components and remodeling 
enzymes in X01 GBM cells and tMSLCs. B. Wound healing assay of X01 GBM cells alone or after coculture with tMSLCs transfected with 
siRNA against VCAN or HAS2. C. Migration of X01 GBM cells alone or after coculture with tMSLCs transfected with siRNA as indicated. 
D. Effect of HA on migration of X01 GBM cells in transwells. E. ELISA for HA levels in X01 GBM cells, tMSLCs or after coculture 
with tMSLC0903. F. ELISA for HA levels in tMSLC0903 after treatment with siRNA as indicated. G. Western blot and semi-quantitative 
RT-PCR for HAS2 levels in X01 GBM cells, tMSLCs or in coculture conditions. X01tMSLC0903 indicates X01 GBM cells cocultured with 
tMSLC0903, and tMSLC0903X01 indicates tMSLC0903 cocultured with X01 GBM cells. Data are presented as mean ± SD from one of 
three independent experiments performed. ***, p < 0.001 vs. control.
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than non-cocultured cells; however, depletion of HAS2 
abolished the effect of tMSLCs on migration of GBM 
cells (Figure 2B). Likewise, GBM cells were also more 
migratory in transwells when cocultured with tMSLCs; 
however, the effect of tMLSCs was diminished by 
transfection with small interfering RNA (siRNA) against 
HAS2, indicating that HAS2 is responsible for the effect 
of tMSLCs on migration of GBM cells (Figure 2C).
Since HAS2 is a rate limiting enzyme for HA 
synthesis, we next validated the effect of HA on migration 
of GBM cells. As expected, exogenous addition of HA 
enhanced migration of GBM cells in a dose dependent 
manner (Figure 2D). Also, when we analyzed HA levels in 
conditioned medium (CM) from tMSLCs and GBM cells, 
HA levels were higher in CM of tMSLCs than that of GBM 
cells (Figure 2E). However, HAS2 depletion significantly 
decreased HA levels in CM of tMSLCs, whereas HAS1 or 
HAS3 had no such effect (Figure 2F). Although coculture 
of tMSLCs with X01 GBM cells slightly increased HAS2 
levels (Figure 2G), its contribution to HA level was not 
significantly observed by enzyme-linked immunosorbent 
assay (ELISA) (Figure 2E). Collectively, these findings 
indicate that tMSLCs contribute to HA-rich ECM 
composition through HAS2 in GBM microenvironment.
Complement factor C5a induces HAS2 in an 
autocrine manner
We next examined a signaling mechanism underlying 
HAS2 regulation in tMSLCs. By previous studies, because 
HAS2 transcription was known to be mainly increased 
by cytokines [20, 21], we analyzed cytokines that are 
able to increase HAS2 in tMSLCs. By cytokine array, 
we noticed the differential levels of interleukin (IL)-
6, IL-8 and C5a between tMSLCs and X01 GBM cells 
(Figure 3A). When each factor was depleted by siRNA, 
Figure 3: C5a induces HAS2 through C5aR1 in tMSLCs. A. Cytokine array in tMLSCs or X01 GBM cells. B. Western blot 
analysis for HAS2 in tMSLC0903 after treatment with siRNA as indicated. C. ELISA for HA levels in tMSLC0903 after treatment with 
siRNA as indicated. D. Western blot analysis for HAS2 in tMSLC0903 after treatment with C5a antibody. E. ELISA for HA levels in 
tMSLC0903 after treatment with C5a antibody. F. Western blot analysis for HAS2 in tMLSC0903 after treatment with siRNA against 
C5aR1. G. ELISA for HA in tMSLC0903 after treatment with siRNA against C5aR1. H. Western blot analysis for HAS2 in X01 GBM cells 
after treatment with rh-C5a. HAS2 in tMLSC0903 is for positive control. S.E., short exposed; L.E., long exposed. I. Western blot analysis 
for C5aR1 in X01, tMSLC0903 or in coculture conditions. J. Migration assay of X01 GBM cells alone or cocultured with tMSLCs in the 
presence of C5a neutralizing antibody. Data are presented as mean ± SD from one of three independent experiments performed. *, p < 0.05 
vs. control; **, p<0.01 vs. control; ***, p < 0.001 vs. control.
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we found that C5 is necessary for HAS2 induction in 
tMSLCs (Figure 3B). In agreement with this result, 
siRNA-mediated C5 depletion effectively diminished HA 
production in tMSLCs, while depletion of IL-6 or -8 had 
no such effect (Figure 3C). Likewise, we examined HA 
and HAS2 levels after treatment with C5a neutralizing 
antibody. Consistent with siRNA, inhibition of C5a with 
the antibody also decreased HA as well as HAS2 levels in 
a dose dependent manner (Figure 3D, 3E). Given that C5a 
secreted by tMSLCs induces HAS2 expression through 
its cognate receptor C5aR1, we next depleted C5aR1 with 
siRNAs in tMSLCs and examined HA and HAS2 levels. 
As expected, C5aR1 knock down caused a decrease in 
HAS2 and HA levels in tMSLCs (Figure 3F, 3G).
In GBM cells, however, exogenous addition of 
recombinant human C5a protein (rh-C5a) did not enhance 
HAS2 levels, implicating that GBM cells are intrinsically 
different from tMSLCS in terms of responsiveness to C5a 
(Figure 3H). Accordingly, we sought to compare levels of 
C5aR1 between tMSLCs and GBM cells. Importantly, we 
found that C5aR1 is highly expressed in tMSLCs, while 
its expression level was substantially lower in GBM cells, 
providing an explanation for why HAS2 is not induced 
by treatment with rh-C5a in GBM cells (Figure 3I). We 
also examined the effect of coculture with tMSLCs; 
however, it did not enhance C5aR1 level in X01 GBM 
cells (Figure 3I).
In agreement with the above results, treatment with 
C5a neutralizing antibody abolished the effect of tMSLCs 
on invasiveness of GBM cells in a dose dependent manner 
(Figure 3J). Collectively, these findings suggest that 
C5a acts as a ligand for C5aR1 for HAS2-mediated HA 
production in tMSLCs.
C5a induces HAS2 through ERK MAPK 
activation in tMSLCs
We next sought to define a signaling mediator in 
tMSLCs for HAS2 induction in response to C5a. To this 
end, we examined, after knockdown of C5 in tMSLCs, 
activation status of several signaling components including 
ERK, PI3K, JAK and STAT3 that are critical regulators 
for mediating a variety of cellular phenomena. Treatment 
with C5 siRNA exclusively inhibited ERK MAPK among 
them (Figure 4A). In parallel, when ERK signaling is 
blocked by treatment with MEK inhibitor U0126, qRT-
PCR analysis revealed that HAS2 transcript was decreased 
in tMSLCs, while other inhibitors against PI3K, JAK or 
Figure 4: C5a-triggered C5aR1 activation induces HAS2 through ERK MAPK. A. Western blot analysis for activation status 
of ERK MAPK, AKT, JAK1 and STAT3 in tMSLCs after treatment with siRNA against C5. B, C. qRT-PCR for HAS2 (B) and ELISA for 
HA (C) levels after pharmacological inhibition of MEK (U0126), PI3K/AKT (LY294002), JAK1 (P6) or STAT3 (WP1066) in tMSLC0903. 
D. Western blot analysis for HAS2 in tMSLCs after treatment with U0126. E. ELISA for HA levels in tMSLC0903 after treatment with 
U0126. F. Western blot analysis for ERK MAPK activation status after treatment with C5a antibody. G. Migration assay of X01 GBM cells 
alone or cocultured with tMSLCs after treatment with siRNA against ERK MAPK. Data are presented as mean ± SD from one of three 
independent experiments performed. *, p < 0.05 vs. control; **, p<0.01 vs. control; ***, p < 0.001 vs. control.
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STAT3 had no such effect (Figure 4B). Consistent with 
these results, inhibition of ERK only caused a decrease in 
HA production in tMSLCs (Figure 4C). To validate that 
ERK is a critical regulator for HA production, we treated 
tMSLCs with a various concentration of MEK inhibitor 
U0126 (0-15 μM), and analyzed HAS2 and HA levels. 
Consistent with the above data, treatment with U0126 
also decreased HAS2 and HA levels in tMSLCs in a dose 
dependent manner (Figure 4D, 4E). In agreement with 
these results, treatment with neutralizing C5a antibody 
inhibited phosphorylation of ERK1/2 (Figure 4F). In 
parallel, ERK depletion in tMSLCs blocked the coculture 
effect on migration of X01 GBM cells (Figure 4G). Taken 
together, these results suggest that C5a induces HAS2 
through ERK MAPK activation in tMSLCs.
HA promotes invasiveness of GBM cells by 
acting as a ligand for RHAMM receptor
Previous studies have reported that many of the 
effects of HA are mediated through cell surface receptors, 
three of which have been molecularly characterized: 
CD44, RHAMM, and ICAM-1 [22]. To understand how 
HA-rich microenvironment facilitates invasiveness of 
GBM cells, we treated tMSLCs with siRNA against 
each HA receptor and analyzed the coculture effect of 
tMSLCs on invasiveness of GBM cells. By migration 
analysis in Transwell, we found that RHAMM, among 
them, is critical for the effect of tMSLCs on migration of 
GBM cells (Figure 5A, 5B). Consistent with this finding, 
RHAMM depletion significantly abolished the effect of 
exogenous HA addition on invasiveness of GBM cells 
(Figure 5C). In addition, we evaluated whether RHAMM 
levels in human brain tumor are correlated with patient 
survival. Evaluation of data in REMBRANDT database 
revealed that expression levels of RHAMM are inversely 
correlated with the survival of patient with brain tumor 
(Figure 5D). Taken together, these results indicate that 
HA promotes phenotypic change of GBM cells into 
invasiveness through RHAMM.
Targeting C5a impedes in vivo infiltration of 
GBM cells
To validate our findings in vivo, we orthotopically 
implanted X01 GBM cells alone or with tMSLCs into 
mouse brain. In agreement with in vitro data, we found that 
GBM cells exhibited more infiltration into parenchymal 
brain following tumor formation when co-injected with 
tMSLCs, as evidenced by histological staining in which 
tumor margin appears to be less distinctive and GBM 
cells are likely to diffuse more to normal tissue, compared 
with tumor formed by GBM cells alone (Figure 6A). An 
immunohistochemical analysis also revealed higher levels of 
C5a and HA in tumors formed by X01 GBM cells combined 
with tMSLCs than in tumors formed by X01 GBM cells 
Figure 5: HA abundance promotes migration of GBM cells through RHAMM receptor. A. Migration assay of X01 GBM 
cells alone or cocultured with tMSLCs after treatment with siRNA as indicated. B. Semi-quantitative RT-PCR for validation of siRNA 
efficacy. C. Migration assay of X01 GBM cells that are transfected with siRNA against RHAMM and treated with various concentration of 
HA. D. Kaplan-Meier survival curves of patients with brain tumors in high and low levels of RHAMM. Data are presented as mean ± SD 
from one of three independent experiments performed. *, p < 0.05 vs. control; **, p<0.01 vs. control; ***, p < 0.001 vs. control.
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alone (Figure 6B). In addition, Immunocytochemical 
staining revealed colocalization of HAS2 with MSC marker 
CD105 in the xenograft tumors, supporting that HAS2 is 
expressed preferentially in tMSLCs (Figure 6C).
To confirm the role of C5a in vivo, we also 
transduced tMSLC09-03 with C5 shRNA or scrambled 
control shRNA prior to orthotopic co-inoculation with 
X01 GBM cells into mouse brains. GBM tumors were 
formed ~5 weeks after implantation of GBM cells. 
As expected, GBM cells co-implanted with tMSLCs 
infiltrated more into normal brain parenchyma than 
GBM cells implanted alone; however, C5 depletion in 
tMSLCs attenuated the effect on GBM cell infiltration 
(Figure 6D). In addition, C5 depletion diminished the 
effect of tMSLCs on HA production in vivo, as evidenced 
by immunohistochemical staining (Figure 6E). Again, we 
observed the colocalization of HAS2 with MSC marker 
CD105 (Figure 6F). Collectively, our findings suggest that 
tMSLCs contribute to abundance of HA in GBM tumor 
microenvironment, and thereby enhances invasiveness of 
GBM cells as depicted in Figure 6G.
DISCUSSION
Although a long-standing focus has been in 
cell-autonomous mechanisms to understand cancer 
progression, paracrine crosstalk between tumor cells and 
stromal cells has begun to be recognized as important 
Figure 6: Correlation of C5a with HAS2 levels in tumor microenvironment. A. H&E staining in coronal-sectioned GBM tumors 
formed by implantation of X01 GBM cells alone or with tMSLCs into mouse brain. Scale bar, 500 μm. B. Immunohistochemical staining of 
C5a and HAS2 in the orthotopic xenograft GBM tumors formed by implantation of X01 GBM cells alone or with tMSLCs into mouse brain. 
Scale bar, 20 μm. C. Immunocytochemical staining showing colocalization of HAS2 with CD105 in the orthotopic xenograft GBM tumors. 
Scale bar, 20 μm. D. H&E staining in coronal-sectioned GBM tumors formed by implantation of X01 GBM cells alone or with tMSLCs into 
mouse brain. tMSLCs were transfected with siRNA as indicated, prior to xenograft. Scale bar, 500 μm. E. Immunohistochemical staining 
of C5a and HAS2 in the orthotopic xenograft GBM tumors formed by implantation of X01 GBM cells alone or with tMSLCs into mouse 
brain. tMSLCs were transfected with siRNA as indicated, prior to xenograft. Scale bar, 20 μm. F. Immunocytochemical staining showing 
colocalization of HAS2 with CD105 in the orthotopic xenograft GBM tumors. Scale bar, 20 μm. G. Schematic model illustrating HA 
production in tMSLCs that enhances invasiveness of GBM cells in tumor microenvironment. T, tumor; N, normal.
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contributors to cancer progression. In line with this 
trend, tMSLCs are recently defined as stromal cells 
interacting with GBM cells and their potential role in 
tumor progression has received intensive attention [11, 
12, 23–25].
Given that tMSLCs were previously isolated from 
human GBM surgical specimens and their presence is 
closely correlated with the prognosis of patients [12], we 
further analyzed the effect of tMSLCs on invasiveness of 
GBM cells. In this current study, we found that tMSLCs 
act as a booster for infiltration of GBM cells by providing 
HA-rich ECM composition in tumor microenvironment. 
By previous studies, the abundance of HA in tumor has 
been proportional to invasiveness of tumor cells [9]. 
Moreover, high levels of HA in stroma are associated with 
poor prognosis of the patients [10]. Despite its clinical 
importance, however, its mechanisms underlying the 
abundance of HA in GBM region remain unexplained. 
Notably, our findings demonstrate that HA abundance in 
tumor microenvironment could be caused by tMSLCs. 
We showed that C5a secreted from tMSLCs activates 
ERK MAPK for HAS2 induction in an autocrine manner, 
thereby increases HA production. Supporting our data, 
previous study has shown that ERK phosphorylation 
is prolonged by C5a in mesenchymal stem cells [26]. 
In agreement, our study showed that targeting of C5a 
effectively decreases ERK MAPK activation and HAS2 
level in tMSLCs, resulting in lowering HA levels.
C5a is well known as a complement component 
that triggers degranulation of mast cells or neutrophils, 
enhancing their phagocytosis of pathogens [18, 27]. 
However, in addition to its primary functions, the 
new functions of C5a in cancer have begun to gain 
attention. Although complement system has been thought 
traditionally to have a role for immune surveillance, 
several strong lines of evidence demonstrated that 
complement factors including C5a contribute to cancer 
progression [27–29]. The involvement of C5a in 
promoting carcinogenesis and metastasis is explained 
by the recruitment of myeloid-derived suppressor cells 
(MDSCs) and the generation of an immunosuppressive 
microenvironment [30]. Our finding that C5a acts as a cue 
for proinvasive tumor microenvironment is in line with 
these previous reports.
As an ECM component, HA was known to act 
as a permissive role in enhancing the invasiveness of 
GBM cells by providing mechanical matrix in tumor 
microenvironment [5, 31]. In addition, HA also acts as a 
signaling component that transduces intracellular signaling 
pathways for invasiveness of GBM cells through its 
cognate receptors such as CD44, RHAMM, and ICAM-
1 [5, 7, 8]. Previously, many studies have shown the 
importance of those HA receptors in GBM progression 
[32–34]. In this current study, our findings revealed that 
HA-rich microenvironment promotes phenotypic changes 
of GBM cells into invasiveness through RHAMM 
receptor, implicating the importance of RHAMM as a HA 
receptor in GBM cells. However, since it was observed 
only in one patient-derived GBM cells, our finding 
does not mean that the effect of HA occurs exclusively 
through RHAMM in GBM cells. In our thoughts, HA 
may transduce intracellular signaling through the cognate 
receptor, depending on status of GBM cells such as the 
receptor levels on membrane.
In summary, we demonstrate that tumor-associated 
MSLCs are responsible for HA abundance in GBM 
microenvironment and act as a booster for invasiveness 
of GBM cells. Considering the effect of HA on survival 
of GBM patients, the mechanisms underlying tMSLC-
mediated HA production merits further investigation.
MATERIALS AND METHODS
Chemical reagents and antibodies
Antibodies to p-ERK1/2, ERK1/2, p-T308-AKT, 
AKT, p-Y705-STAT3, JAK1 were purchased from Cell 
Signaling Technology (Beverly, MA, USA). STAT3 
and p-T1022-JAK1 were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Antibodies 
to HAS2 and C5R1 were purchased from Abcam 
(Cambridge, UK). 4,6-diamidino-2-phenylindole (DAPI) 
were purchased form Sigma (St Louis, MO, USA). rh-C5a 
protein and antibodies to CD105 and C5a were purchased 
from R&D Systems (Minneapolis, MN, USA). Chemical 
inhibitors specific to MEK (U0126), PI3K (LY294002), 
JAK1 (P6) and STAT3 (WP1066) were purchased from 
Calbiochem (San Diego, CA, USA). Anti-Goat Alexa 
Fluor 488, anti-mouse Alexa Fluor 546 were purchased 
from Invitrogen (Carlsbad, CA, USA). Anti-mouse IgG-
HRP, anti-goat IgG-HRP and anti-rabbit Ig-HRP were 
purchased from Santa Cruz biotechnology (Santa Cruz, 
CA, USA). HA (Low molecular weight; 15-40 kDa) was 
purchased from R&D systems (Minneapolis, MN, USA).
Co-culture of tMSLC and GBM cells
tMSLC0903 (2.5 × 105) were seeded onto the upper 
chamber and X01 GBM cells (1.5 × 105) into the lower 
chamber in Transwell with a pore size 0.4 μm. Migration 
was analyzed 3 days after co-culture.
Culture of GBM cells and tMSLCs
The patient-derived X01 GBM cells were 
established from acutely resected human tumor tissues 
obtained with written informed consent from a 68-year-old 
woman with GBM [35]. X01 GBM cells were cultured in 
Dulbecco’s modified Eagle Medium (Gibco, Korea, Seoul) 
containing 1% penicillin and streptomycin, supplemented 
with 10% heat-inactivated fetal bovine serum (Lonza, 
Basel, Switzerland).
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tMSLC09-03 (previously referred as KGS-
MSC05-04) have been isolated from biopsy of GBM 
patient [23]. All non-adherent cells were washed 
away with phosphate-buffered saline (PBS) and only 
adherent tMSLCs were cultured in MEMα (Mediatech) 
containing 10% FBS (Lonza), 2 mM L-glutamine 
(Mediatech), and antibiotic–antimycotic solution 
(Gibco, Seoul, Korea).
Migration assay
Migration properties of GBM cells were 
analyzed in transwell (8 μm pore size; Corning Glass, 
Seoul, Korea). GBM cells (2 × 104) were loaded in 
the upper well of the transwell and were incubated for 
24 h. The migrated cells into the lower surface of the 
filter were then fixed and stained with a Diff Quick 
kit (Fisher, Pittsburgh, PA, USA). The number of 
migrated cells was counted in three microscopic fields 
per well.
Organotypic invasion of GBM cells in ECM 
conditioned by tMSLCs
tMSLC0903 were seeded into the collagen-based 
matrix, and cultured for 3 days for tMSLC0903-caused 
ECM remodeling. Afterwards, tMSLC0903 were killed 
by treatment with puromycin, but leaving tMSLC-secreted 
ECM composition. X01 GBM cells were then plated in 
the conditioned ECM, and their invasion was visualized 
at 48 h by H&E staining after perpendicular section of the 
gels. The number of invaded cells was counted in three 
microscopic fields per well.
Cytokine array
The human cytokine array (Proteome Profiler Array 
Human Cytokine, R&D Systems, ARY005, Minneapolis, 
MN, USA) was performed according to the manufacturer’s 
instructions. Those cytokine levels were visualized in the 
X-ray film and quantified by densitometry using Image J 
software.
ELISA
CM was collected 3 days after plating X01 GBM 
cells or tMSLCs, and the secreted HA in CM was 
quantified by ELISA (human HA ELISA Kit, R&D 
Systems) according to the manufacturer's protocol.
Transfection
Cells were transfected with siRNA using a 
Microporator-mini (Digital Bio Technology, Seoul, 
Korea) according to the procedure recommended by 
the manufacturer. All siRNAs were purchased from 
Genolution Pharmaceuticals, Inc (Seoul, Korea).
Western blot analysis
Cell lysates were prepared by extracting proteins 
with lysis buffer [40 mM Tris–HCl (pH 8.0), 120 mM 
NaCl, 0.1% Nonidet-P40] supplemented with protease 
inhibitors. Proteins were separated by SDS-PAGE, and 
transferred to a nitrocellulose membrane (Amersham, 
Arlington Heights, IL, USA). The membrane was blocked 
with 5% non-fat dry milk in Tris-buffered saline, and 
incubated with primary antibodies overnight at 4 °C. 
Blots were developed with a peroxidase-conjugated 
secondary antibody, and proteins visualized by enhanced 
chemiluminescence (ECL) procedures (Amersham), using 
the manufacturer's protocol.
RT-PCR
Total RNA was isolated using the Trizol 
(Invitrogen). RNA was subjected to reverse transcription 
using SuperScript III First-Strand Synthesis SuperMix 
(Invitrogen). Gene expression levels were analyzed by 
PCR using Econo Taq Plus Green (Lucigen, Seoul, Korea). 
β-actin was used as an internal control for each sample.
Immunohistochemistry
Mouse tissues were fixed in formalin for the 
preparation of paraffin sections. Paraffin-embedded tissue 
sections were deparaffinized in xylene, 95, 90, and 70% 
ethanol, followed by PBS. Epitopes were unmasked with 
20 mg/mL proteinase K in PBS with 0.1% Triton X-100. 
Sections were stained with H&E or immunostained overnight 
at 4 °C with primary antibody. After washing in PBS, 
biotinylated goat anti-rabbit IgG or anti-mouse IgG antibody 
was then applied to the sections for 30 min. After washing 
in PBS, ABC reagent (Vector Laboratories Inc, Burlingame, 
CA, USA) was applied to the sections for 30 min. Color 
reaction was performed with 3, 3'-diaminobenzidine (Vector 
Laboratories). After counter-staining with hematoxylin and 
clearing with graded ethanol series and xylene, the sections 
were mounted with Canada balsam.
Alternatively, tissues were incubated with primary 
antibody at 4°C overnight. Samples were then visualized 
by staining with anti-mouse Alexa Flour488 and anti-
goat Alexa Flour546 (Molecular Probes, Seoul, Korea). 
Nuclei were counterstained using DAPI (Sigma, St. 
Louis, MO, USA). Images were captured with Nikon 
confocal microscope C2 installed at the Hanyang Center 
for Research Facilities (Seoul), and analyzed with NIS-
Elements Viewer 4.2 (Nikon Instruments, Tokyo, Japan).
Animal studies
5 to 8-weeks-old male athymic nude mice (Central 
Lab. Animal Inc., Seoul, Korea) were used to check 
tumorigenesis of GBM cells and tMSLCs. Mice were 
housed in microisolator cages under sterile conditions 
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and observed for at least 1 week before study initiation to 
ensure proper health. GBM cells alone or combined with 
tMSLC0903 (1:1 ratio) were injected at a speed of 0.5 μl/
min into the right frontal lobe of mouse skull via a Hamilton 
syringe (Dongwoo Science Co., Seoul, Korea) using a 
guide-screw system, as described previously [23, 36, 37].
Kaplan-meier survival analysis
The National Cancer Institute’s Repository for 
Molecular Brain Neoplasia Data (REMBRANDT, 
http://www.betastasis.com/glioma/rembrandt, accessed 
November 2016) was evaluated for correlations between 
clinical outcome/survival and RHAMM gene expression 
in human brain tumor biopsies. For REMBRANDT, “high 
expression” is defined as upper than threshold 6.31; “low 
expression” is defined as lower than the threshold.
Statistical analysis
All experimental data are reported as means; error 
bars represent standard deviation (SD). Comparisons 
between values were performed using unpaired two-tailed 
Student’s t-test, or ANOVA for multivariate analysis. All 
statistical analyses were performed using GraphPad Prism 
7.0 and the p values <0.05 were considered significant.
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